Indapta Therapeutics treats first subjects in Phase I cancer therapy trial

Indapta Therapeutics has commenced the Phase I clinical trial of natural killer (NK) cell therapy IDP-023, treating the first patients with multiple myeloma and non-Hodgkin’s lymphoma.